The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management

Overview

Journal Adv Pharm Bull

Date 2024 Aug 29

PMID 39206402

Authors

Dito Anurogo

Dewi Luthfiana

Nuralfin Anripa

Apriliani Ismi Fauziah

Maratu Soleha

Laila Rahmah

Hana Ratnawati

Teresa Liliana Wargasetia

Sari Eka Pratiwi

Riswal Nafi Siregar

Ratis Nour Sholichah

Muhammad Sobri Maulana

Taruna Ikrar

Yu Hsiang Chang

Jiantai Timothy Qiu

Affiliations

Soon will be listed here.

Abstract

Purpose: Lymphoma, the most predominant neoplastic disorder, is divided into Hodgkin and Non-Hodgkin Lymphoma classifications. Immunotherapeutic modalities have emerged as essential methodologies in combating lymphoid malignancies. Chimeric Antigen Receptor (CAR) T cells exhibit promising responses in chemotherapy-resistant B-cell non-Hodgkin lymphoma cases.

Methods: This comprehensive review delineates the advancement of CAR-T cell therapy as an immunotherapeutic instrument, the selection of lymphoma antigens for CAR-T cell targeting, and the conceptualization, synthesis, and deployment of CAR-T cells. Furthermore, it encompasses the advantages and disadvantages of CAR-T cell therapy and the prospective horizons of CAR-T cells from a computational research perspective. In order to improve the design and functionality of artificial CARs, there is a need for TCR recognition investigation, followed by the implementation of a quality surveillance methodology.

Results: Various lymphoma antigens are amenable to CAR-T cell targeting, such as CD19, CD20, CD22, CD30, the kappa light chain, and ROR1. A notable merit of CAR-T cell therapy is the augmentation of the immune system's capacity to generate tumoricidal activity in patients exhibiting chemotherapy-resistant lymphoma. Nevertheless, it also introduces manufacturing impediments that are laborious, technologically demanding, and financially burdensome. Physical, physicochemical, and physiological limitations further exacerbate the challenge of treating solid neoplasms with CAR-T cells.

Conclusion: While the efficacy and safety of CAR-T cell immunotherapy remain subjects of fervent investigation, the promise of this cutting-edge technology offers valuable insights for the future evolution of lymphoma treatment management approaches. Moreover, CAR-T cell therapies potentially benefit patients, motivating regulatory bodies to foster international collaboration.

References

Cottereau A, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L . Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT. Ann Oncol. 2020; 32(3):404-411. DOI: 10.1016/j.annonc.2020.11.019. View

Ratajczak W, Niedzwiedzka-Rystwej P, Tokarz-Deptula B, Deptula W . Immunological memory cells. Cent Eur J Immunol. 2018; 43(2):194-203. PMC: 6102609. DOI: 10.5114/ceji.2018.77390. View

Wei J, Han X, Bo J, Han W . Target selection for CAR-T therapy. J Hematol Oncol. 2019; 12(1):62. PMC: 6587237. DOI: 10.1186/s13045-019-0758-x. View

Schmieg J, Muir J, Aguilera N, Auerbach A . CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen. Curr Oncol. 2021; 28(6):5124-5147. PMC: 8700451. DOI: 10.3390/curroncol28060430. View

Page S, Cunningham D, Plow E, Blazak B . It takes two: noninvasive brain stimulation combined with neurorehabilitation. Arch Phys Med Rehabil. 2015; 96(4 Suppl):S89-93. PMC: 4445084. DOI: 10.1016/j.apmr.2014.09.019. View

Singh R, Shaik S, Negi B, Rajguru J, Patil P, Parihar A . Non-Hodgkin's lymphoma: A review. J Family Med Prim Care. 2020; 9(4):1834-1840. PMC: 7346945. DOI: 10.4103/jfmpc.jfmpc_1037_19. View

Frey N, Porter D . The Promise of Chimeric Antigen Receptor T-Cell Therapy. Oncology (Williston Park). 2016; 30(10):880-8, 890. View

Kochenderfer J, Dudley M, Carpenter R, Kassim S, Rose J, Telford W . Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013; 122(25):4129-39. PMC: 3862276. DOI: 10.1182/blood-2013-08-519413. View

Chen Y, Cheng Y, Suo P, Yan C, Wang Y, Chen Y . Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell.... Br J Haematol. 2017; 179(4):598-605. DOI: 10.1111/bjh.14923. View

10.

Ramos C, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O . Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest. 2016; 126(7):2588-96. PMC: 4922690. DOI: 10.1172/JCI86000. View

11.

Choi G, Shin G, Bae S . Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy. Int J Environ Res Public Health. 2022; 19(19). PMC: 9566791. DOI: 10.3390/ijerph191912366. View

12.

Kim M, Yu K, Kenderian S, Ruella M, Chen S, Shin T . Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018; 173(6):1439-1453.e19. PMC: 6003425. DOI: 10.1016/j.cell.2018.05.013. View

13.

Tong Y, Udupa J, Chong E, Winchell N, Sun C, Zou Y . Prediction of lymphoma response to CAR T cells by deep learning-based image analysis. PLoS One. 2023; 18(7):e0282573. PMC: 10361488. DOI: 10.1371/journal.pone.0282573. View

14.

Hudecek M, Schmitt T, Baskar S, Lupo-Stanghellini M, Nishida T, Yamamoto T . The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010; 116(22):4532-41. PMC: 2996114. DOI: 10.1182/blood-2010-05-283309. View

15.

Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lemaitre F . A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol. 2021; 6(57). DOI: 10.1126/sciimmunol.abd4344. View

16.

Srivastava S, Salter A, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K . Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. Cancer Cell. 2019; 35(3):489-503.e8. PMC: 6450658. DOI: 10.1016/j.ccell.2019.02.003. View

17.

Vandghanooni S, Eskandani M, Sanaat Z, Omidi Y . Recent advances in the production, reprogramming, and application of CAR-T cells for treating hematological malignancies. Life Sci. 2022; 309:121016. DOI: 10.1016/j.lfs.2022.121016. View

18.

Tubic B, Jungic S . Regulatory aspects of biological medicines in Bosnia and Herzegovina. Bosn J Basic Med Sci. 2022; 22(4):511-522. PMC: 9392977. DOI: 10.17305/bjbms.2021.6910. View

19.

Buechner J, Kersten M, Fuchs M, Salmon F, Jager U . Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe. Hemasphere. 2019; 2(1):e18. PMC: 6745952. DOI: 10.1097/HS9.0000000000000018. View

20.

Qasim W . Allogeneic CAR T cell therapies for leukemia. Am J Hematol. 2019; 94(S1):S50-S54. DOI: 10.1002/ajh.25399. View